Taiwan · Delayed Price · Currency is TWD OK Biotech Statistics
Total Valuation
OK Biotech has a market cap or net worth of TWD 2.29 billion. The enterprise value is 2.90 billion.
| Market Cap | 2.29B |
| Enterprise Value | 2.90B |
Important Dates
The next estimated earnings date is Monday, August 11, 2025.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | Jul 4, 2025 |
Share Statistics
OK Biotech has 142.06 million shares outstanding. The number of shares has increased by 6.77% in one year.
| Current Share Class | 142.06M |
| Shares Outstanding | 142.06M |
| Shares Change (YoY) | +6.77% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 6.78% |
| Owned by Institutions (%) | 0.60% |
| Float | 106.12M |
Valuation Ratios
The trailing PE ratio is 28.36.
| PE Ratio | 28.36 |
| Forward PE | n/a |
| PS Ratio | 1.33 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 18.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.23, with an EV/FCF ratio of -8.60.
| EV / Earnings | 35.10 |
| EV / Sales | 1.68 |
| EV / EBITDA | 20.23 |
| EV / EBIT | 42.63 |
| EV / FCF | -8.60 |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.91 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 6.01 |
| Debt / FCF | -2.52 |
| Interest Coverage | 9.39 |
Financial Efficiency
Return on equity (ROE) is 3.84% and return on invested capital (ROIC) is 1.35%.
| Return on Equity (ROE) | 3.84% |
| Return on Assets (ROA) | 1.19% |
| Return on Invested Capital (ROIC) | 1.35% |
| Return on Capital Employed (ROCE) | 2.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.98 |
Taxes
In the past 12 months, OK Biotech has paid 21.67 million in taxes.
| Income Tax | 21.67M |
| Effective Tax Rate | 18.50% |
Stock Price Statistics
The stock price has decreased by -40.07% in the last 52 weeks. The beta is 0.09, so OK Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -40.07% |
| 50-Day Moving Average | 16.97 |
| 200-Day Moving Average | 20.13 |
| Relative Strength Index (RSI) | 43.56 |
| Average Volume (20 Days) | 83,011 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OK Biotech had revenue of TWD 1.73 billion and earned 82.67 million in profits. Earnings per share was 0.57.
| Revenue | 1.73B |
| Gross Profit | 338.34M |
| Operating Income | 65.90M |
| Pretax Income | 117.16M |
| Net Income | 82.67M |
| EBITDA | 135.90M |
| EBIT | 65.90M |
| Earnings Per Share (EPS) | 0.57 |
Balance Sheet
The company has 314.83 million in cash and 848.49 million in debt, giving a net cash position of -533.66 million or -3.76 per share.
| Cash & Cash Equivalents | 314.83M |
| Total Debt | 848.49M |
| Net Cash | -533.66M |
| Net Cash Per Share | -3.76 |
| Equity (Book Value) | 2.55B |
| Book Value Per Share | 16.86 |
| Working Capital | 715.58M |
Cash Flow
In the last 12 months, operating cash flow was 126.49 million and capital expenditures -463.84 million, giving a free cash flow of -337.35 million.
| Operating Cash Flow | 126.49M |
| Capital Expenditures | -463.84M |
| Free Cash Flow | -337.35M |
| FCF Per Share | -2.37 |
Margins
Gross margin is 19.56%, with operating and profit margins of 3.81% and 4.78%.
| Gross Margin | 19.56% |
| Operating Margin | 3.81% |
| Pretax Margin | 6.77% |
| Profit Margin | 4.78% |
| EBITDA Margin | 7.85% |
| EBIT Margin | 3.81% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.86%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 1.86% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 53.37% |
| Buyback Yield | -6.77% |
| Shareholder Yield | -4.93% |
| Earnings Yield | 3.60% |
| FCF Yield | -14.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2023. It was a forward split with a ratio of 1.10213412.
| Last Split Date | Sep 6, 2023 |
| Split Type | Forward |
| Split Ratio | 1.10213412 |
Scores
OK Biotech has an Altman Z-Score of 2.46 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.46 |
| Piotroski F-Score | 6 |